Printer Friendly

Browse Rilpivirine topic

Articles

1-92 out of 92 article(s)
Title Author Type Date Words
New 'long acting' HIV treatment means virus can be managed with injections 6 times a year; Charities have hailed the "incredible news" after NHS bosses were given the green light to offer cabotegravir to an estimated 13,000 people. By, Ella Pickover Nov 18, 2021 745
13,000 people with HIV in England to be offered new treatment; The treatment will replace daily drugs with a long-term injection. By, Neil Shaw Nov 18, 2021 708
ViiV Healthcare Inks Exclusive License Agreement with Shionogi to Develop Third-Generation HIV Integrase Inhibitor with Potential for Ultra Long-Acting Dosing Intervals. Sep 28, 2021 396
ViiV Healthcare presents findings from CUSTOMIZE trial. Jul 18, 2021 306
The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report. Bianchelli, Tommaso; Campanati, Anna; Sapigni, Claudia; Costantini, Andrea; Butini, Luca; Radi, Giul Apr 1, 2021 2235
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva as an HIV Treatment for Use Every 2-Months. Feb 24, 2021 303
GlaxoSmithKline says ViiV receives US FDA approval for long-acting HIV regimen. Jan 23, 2021 311
More countries approve once-a-month ARV. Jan 23, 2021 500
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva. Jan 22, 2021 254
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva. Jan 22, 2021 250
TOP NEWS: Glaxo, Johnson & Johnson Long-Acting HIV Drug Approved In US. Jan 22, 2021 325
LONDON BRIEFING: UK Retail Sales And Govt Debt Set Unwelcome Records. Jan 22, 2021 1885
US FDA Approves Cabenuva as Long-Acting Regimen for the Treatment of HIV. Jan 22, 2021 454
ViiV Healthcare Gains FDA Approval of Cabenuva as long-Acting Regimen for HIV Treatment. Jan 22, 2021 847
GlaxoSmithKline-owned ViiV Healthcare receives green light for long-acting HIV treatment. Dec 22, 2020 239
European Commission Authorises the First Complete Long-Acting Injectable HIV Treatment in Europe. Dec 22, 2020 850
CAB/RPV 4-week, 8-week injections safe, effective in women. Haelle, Tara Nov 1, 2020 525
ViiV Healthcare announces once-monthly injectable HIV treatment implementation science study positive findings. Oct 23, 2020 314
ViiV Healthcare announces once-monthly injectable HIV treatment implementation science study positive findings. Oct 23, 2020 318
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV. Oct 21, 2020 455
Janssen receives CHMP opinion recommending MA for Rekambys with Vocabria. Oct 16, 2020 286
Pneumocystis jirovecii Pneumonia in a HIV-infected Patient with a CD4 Count Greater Than 400 Cells/[micro]L and Atovaquone Prophylaxis. Sullivan, Abigayle; Lanham, Theresa; Krol, Ronald; Zachariah, Shilla Jul 31, 2020 1756
Neutrophilic eccrine hidradenitis attributed to HIV treatment. Jancin, Bruce Jun 1, 2020 370
Health Canada approves Janssen Pharmaceutical's CABENUVA. Mar 23, 2020 154
Health Canada approves Janssen Pharmaceutical's CABENUVA. Mar 23, 2020 158
ViiV Healthcare receives Health Canada approval for Cabenuva. Mar 20, 2020 154
GlaxoSmithKline Notes Positive HIV Study Results, Partnership Renewal. Mar 10, 2020 554
ViiV Healthcare says phase III ATLAS-2M study meets primary endpoint. Mar 9, 2020 193
GlaxoSmithKline target price upped by UBS due to HIV drug. Feb 1, 2020 319
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia[R] Launch. Jan 27, 2020 2538
RedHill Biopharma to Focus Commercial Efforts on Talicia[R] and Aemcolo[R]; Discontinuing Promotion of Legacy Products. Jan 21, 2020 2150
GlaxoSmithKline receives HIV treatment knock-back in the USA. Dec 24, 2019 263
ViiV Healthcare Receives Complete Response Letter from US FDA for Use of Investigational Cabotegravir and Rilpivirine Long-Acting Regimen in the Treatment of HIV. Dec 24, 2019 298
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV. Dec 23, 2019 390
GLOBAL BRIEFING: China Eases Tariffs On Wide Range Of Goods. Dec 23, 2019 1942
LONDON MARKET PRE-OPEN: NMC Health Plans Review; Intu's Spanish Sale. Dec 23, 2019 1178
LONDON BRIEFING: Nichols In Profit Warning Due To Tax On Sweet Drinks. Dec 23, 2019 1699
UK WINNERS & LOSERS SUMMARY: NMC Surges On Plan For Independent Review. Dec 23, 2019 846
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. Dec 13, 2019 958
GlaxoSmithKline (LSE: GSK). Nov 12, 2019 17527
GlaxoSmithKline (LSE: GSK). Nov 11, 2019 16581
GlaxoSmithKline (LSE: GSK). Nov 6, 2019 16607
GlaxoSmithKline (LSE: GSK). Nov 4, 2019 16581
RedHill Biopharma Announces FDA Approval of Talicia[R] for Treatment of H. pylori in Adults. Nov 4, 2019 3113
GlaxoSmithKline (LSE: GSK). Oct 29, 2019 16571
GlaxoSmithKline (LSE: GSK). Oct 28, 2019 16578
GlaxoSmithKline (LSE: GSK). Oct 22, 2019 16570
GlaxoSmithKline (LSE: GSK). Oct 21, 2019 16574
GlaxoSmithKline (LSE: GSK). Oct 15, 2019 16569
GlaxoSmithKline (LSE: GSK). Oct 8, 2019 16574
GlaxoSmithKline (LSE: GSK). Oct 2, 2019 16570
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV; Presentations include six-year data for the investigational regimen of cabotegravir ... Oct 2, 2019 2515
GlaxoSmithKline (LSE: GSK). Sep 24, 2019 16577
GlaxoSmithKline (LSE: GSK). Sep 18, 2019 14045
GlaxoSmithKline (LSE: GSK). Sep 11, 2019 14042
GlaxoSmithKline (LSE: GSK). Sep 3, 2019 14043
GlaxoSmithKline (LSE: GSK). Aug 27, 2019 14046
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months. Aug 23, 2019 654
ViiV Healthcare says phase III ATLAS-2M study met primary endpoint. Aug 22, 2019 184
The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study. Aug 22, 2019 944
Glaxo's ViiV Reports Positive Study Results Of HIV-Treatment Regimen. Aug 22, 2019 269
GlaxoSmithKline (LSE: GSK). Aug 20, 2019 14042
GlaxoSmithKline (LSE: GSK). Aug 14, 2019 14044
GlaxoSmithKline (LSE: GSK). Aug 6, 2019 14045
GlaxoSmithKline (LSE: GSK) - ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV -- 29/7/2019. Aug 1, 2019 502
GlaxoSmithKline (LSE: GSK). Aug 1, 2019 14044
Glaxo's ViiV Healthcare Seeks European Approval For Cabotegravir. Jul 29, 2019 220
ViiV Healthcare commences trial to identify and evaluate approaches for implementation of once-monthly HIV treatment. Jul 10, 2019 210
ViiV Healthcare commences trial to identify and evaluate approaches for implementation of once-monthly HIV treatment. Jul 10, 2019 206
GlaxoSmithKline (LSE: GSK). Jul 9, 2019 14163
GlaxoSmithKline (LSE: GSK). Jun 25, 2019 14163
GlaxoSmithKline (LSE: GSK). Jun 18, 2019 14163
GlaxoSmithKline (LSE: GSK). Jun 13, 2019 14164
GlaxoSmithKline (LSE: GSK). Jun 4, 2019 14164
GlaxoSmithKline (LSE: GSK). May 29, 2019 14160
GlaxoSmithKline (LSE: GSK). May 21, 2019 14164
Novel injectable HIV therapy noninferlor to oral regimen. Kling, Jim May 1, 2019 804
ViiV Healthcare seeks US FDA approval for two-drug HIV treatment. May 1, 2019 203
ViiV Healthcare seeks US FDA approval for two-drug HIV treatment. May 1, 2019 199
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV. Apr 30, 2019 778
GlaxoSmithKline (LSE: GSK). Apr 30, 2019 14164
ViiV Healthcare submits NDA for two-drug regimen of cabotegravir, rilpivirine. Apr 29, 2019 211
GlaxoSmithKline (LSE: GSK). Apr 23, 2019 14166
GlaxoSmithKline (LSE: GSK). Apr 16, 2019 14165
ViiV Healthcare reveals three-year results from SWORD 1 & 2 Juluca studies at British HIV Association's 25th Annual Conference. Conference news Apr 5, 2019 241
ViiV Healthcare reveals three-year results from SWORD 1 & 2 Juluca studies at British HIV Association's 25th Annual Conference. Conference news Apr 5, 2019 237
GSK's ViiV Healthcare says ATLAS Phase III study met primary endpoint. Mar 8, 2019 159
J&J says rilpivirine/cabotegravir met primary endpoints in two Phase 3 studies. Mar 7, 2019 170
Stability-indicating HPLC method for the simultaneous determination of HIV tablet containing emtricitabine, tenofovir disoproxil fumarate, and rilpivirine hydrochloride in pharmaceutical dosage forms. Venkatesan, S.; Kannappan, N.; Mannemala, Sai Sandeep Report Jan 1, 2014 5280
FDA gives green light to Edurant for HIV treatment. May 23, 2011 221
FDA greenlights Tibotec's HIV medicine Edurant. May 20, 2011 339
Rilpivirine shows efficacy; safety in HIV patients. Zoler, Mitchel L. Clinical report Nov 1, 2010 609

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |